These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34311397)

  • 1. Influence of nitisinone and its metabolites on l-tyrosine metabolism in a model system.
    Płonka J; Babiuch M; Barchanska H
    Chemosphere; 2022 Jan; 286(Pt 1):131592. PubMed ID: 34311397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profiles and fingerprints for the investigation of the influence of nitisinone on the metabolism of the yeast Saccharomyces cerevisiae.
    Barchanska H; Płonka J; Nowak P; Kostina-Bednarz M
    Sci Rep; 2023 Jan; 13(1):1473. PubMed ID: 36702867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL
    Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS/MS study of the degradation processes of nitisinone and its by-products.
    Barchanska H; Rola R; Szczepankiewicz W; Mrachacz M
    J Pharm Biomed Anal; 2019 Jul; 171():15-21. PubMed ID: 30959315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.
    Lock EA; Gaskin P; Ellis MK; Provan WM; Robinson M; Smith LL; Prisbylla MP; Mutter LC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):439-47. PubMed ID: 8975769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.
    Lock EA; Gaskin P; Ellis MK; McLean Provan W; Robinson M; Smith LL
    Toxicology; 2000 Apr; 144(1-3):179-87. PubMed ID: 10781886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
    Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.
    Kavana M; Moran GR
    Biochemistry; 2003 Sep; 42(34):10238-45. PubMed ID: 12939152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.
    Lock EA; Gaskin P; Ellis M; Provan WM; Smith LL
    Toxicol Appl Pharmacol; 2006 Aug; 215(1):9-16. PubMed ID: 16580702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.
    Lock EA; Gaskin P; Ellis MK; Robinson M; Provan WM; Smith LL
    Toxicol Appl Pharmacol; 1998 May; 150(1):125-32. PubMed ID: 9630461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 2-[2-nitro-4-(trifluoromethyl)benzoyl]- cyclohexane-1,3-dione metabolites in urine of patients suffering from tyrosinemia type I with the use of 1H and 19F NMR spectroscopy.
    Szczeciński P; Lamparska D; Gryff-Keller A; Gradowska W
    Acta Biochim Pol; 2008; 55(4):749-52. PubMed ID: 19039335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
    Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
    Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic profiles in the course of the shikimic acid pathway of Raphanus sativus var. longipinnatus exposed to mesotrione and its degradation products.
    Płonka J; Górny A; Kokoszka K; Barchanska H
    Chemosphere; 2020 Apr; 245():125616. PubMed ID: 31864055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures.
    Prieto JA; Andrade F; Lage S; Aldámiz-Echevarría L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):671-6. PubMed ID: 21377430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
    Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of NTBC metabolites in urine from patients with hereditary tyrosinemia type 1 using two different mass spectrometric platforms: triple stage quadrupole and LTQ-Orbitrap.
    Herebian D; Lamshöft M; Mayatepek E; Spiekerkoetter U
    Rapid Commun Mass Spectrom; 2010 Mar; 24(6):791-800. PubMed ID: 20187082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
    Hanauske-Abel HM; Popowicz A; Remotti H; Newfield RS; Levy J
    J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):73-8. PubMed ID: 12142814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Weed Killer to Wonder Drug.
    Lock EA
    Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.